Routine ICU Surveillance after Brain Tumor Surgery: Patient Selection Using Machine Learning
Source check: Source checked. Not independent scientific confirmation.
Finding / tested result: XGBoost predicted early adverse events after brain-tumor surgery in a retrospective cohort of 1,000 patients; preoperative-only cross-validated ROC-AUC was 0.76 and combined pre/postoperative AUC 0.81. The outcome is a specific patient-selection question, with retrospective single-center validation limits.
Technology: XGBoost gradient boosting on 27 perioperative features; retrospective 1,000 consecutive adult tumor resections. Repeated 5×5 CV; nine adverse-event/intervention outcomes within 24 hours; pre-op-only AUC 0.76, combined pre/post-op AUC 0.81.
Publication: Publication status unspecified in annotation · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- XGBoost gradient boosting on 27 perioperative features; retrospective 1,000 consecutive adult tumor resections. Repeated 5×5 CV; nine adverse-event/intervention outcomes within 24 hours; pre-op-only AUC 0.76, combined pre/post-op AUC 0.81.
- Limitation / still unknown
- The result is limited to the reported dataset, experimental setting and validation in this study; broader generalization and real-world benefit are not established.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://mdpi-res.com/d_attachment/jcm/jcm-13-05747/article_deploy/jcm-13-05747.pdf
The legacy label “Not reported” does not distinguish information absent from reviewed material from information not assessed. It is not a scientific finding of absence.
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.